There are different BCR-ABL1 fusion genes that are translated into proteins that are different from each other, yet all leukemogenic, causing chronic myeloid leukemia (CML) or acute lymphoblastic leukemia. Their frequency has never been systematically investigated. In a series of 45503 newly diagnosed CML patients reported from 45 countries, it was found that the proportion of e13a2 (also known as b2a2) and of e14a2 (also known as b3a2), including the cases co-expressing e14a2 and e13a2, was 37.9% and 62.1%, respectively. The proportion of these two transcripts was correlated with gender, e13a2 being more frequent in males (39.2%) than in females (36.2%), was correlated with age, decreasing from 39.6% in children and adolescents down to 31.6% in patients ≥ 80 years old, and was not constant worldwide. Other, rare transcripts were reported in 666/34561 patients (1.93%). The proportion of rare transcripts was associated with gender (2.27% in females and 1.69% in males) and with age (from 1.79% in children and adolescents up to 3.84% in patients ≥ 80 years old). These data show that the differences in proportion are not by chance. This is important, as the transcript type is a variable that is suspected to be of prognostic importance for response to treatment, outcome of treatment, and rate of treatment-free remission.
Subscribe to Journal
Get full journal access for 1 year
only $102.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Melo JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375–84.
Chereda B, Melo JV. The biology and pathogenesis of chronic myeloid leukemia. In: Hehlmann R, editor, Chronic myeloid leukemia. Springer International Publishing, Switzerland, 2016. p.17–40.
Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, et al. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib. Haematologica. 2014;99:1441–7.
The ICSG on CML. Chronic myeloid leukemia, BCR/ABL transcript, response to α-interferon, and survival. Leukemia. 1995;9:1648–51.
Baccarani M, Rosti G, de Vivo A, Bonifazi F, Russo D, Martinelli G, et al. A randomized study of interferon-α versus interferon-α and low dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002;99:1527–35.
Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia. 2015;29:1823–31.
Castagnetti F, Gugliotta G, Palandri F, Breccia M, Stagno F, Levato L, et al. The BCR-ABL1 transcript type does not influence the response and the outcome of chronic myeloid leukemia patients treated frontline with nilotinib. 54th Annual Meeting of the American Society of Hematology. Blood. 2012;120:1680.
Cervantes F, Lopez-Garrido P, Montero M-I, Jonte F, Martinez J, Hernandez-Boluda I-C, et al. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA Group. Haematologica. 2010;95:1317–24.
Shepherd P, Suffolk R, Halsey J, Allan N. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol. 1995;89:546–54.
Bonifacio M, Scaffidi L, Binotto G, De Marchi F, Maino E, Calistri E, et al. Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with standard dose imatinib: a study from the “Gruppo Triveneto LMC”. 57th Congress of the American Society of Hematology. Blood. 2015;126:597.
Castagnetti F, Di Raimondo F, De Vivo A, Spitaleri A, Gugliotta G, Fabbiano F, et al. A population-based study of chronic myeloid leukemia patients treated with imatinib in first line. Am J Hematol. 2017;92:82–87.
Osorio S, Casado LF, Giraldo P, Maestro N, Andrade M, Redondo S, et al. Chronic myeloid leukaemia in Spain: its presentation characteristics have changed. Spanish Section of the EUTOS population-based registry. Rev Clin Esp. 2016;216:293–300.
Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries. Leukemia. 2015;29:1336–43.
Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, et al. No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib. J Cancer Res Clin Oncol. 2017;143:843–50.
Kim D, Goh HG, Kim S-H, Choi S-Y, Park S-H, Jang E-J, Kim D-W. Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendations. Int J Hematol. 2012;96:47–57.
Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, et al. Chronic myeloid leukaemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 2009;94:1362–7.
de Lavallade H, Apperley JF, Khorashad JS, Milojkovic D, Reid AG, Bua M, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008;26:3359–63.
Marin D, Gabriel IH, Ahmad S, Fioroni L, de Lavallade H, Clark R, et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia. 2012;26:296–302.
Jain P, Kantarjian H, Patel KP, Nogueras Gonzales G, Luthra R, Shamanna RK, et al. Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016;127:1269–75.
Pagnano KBB, Miranda EC, Delamain MT, Duarte GO, de Paula EV, Lorand-Metze I, de Souza CA. Influence of BCR-ABL transcript type on outcome in patients with chronic phase chronic myeloid leukemia treated with imatinib. Clinical Lymphoma, Myeloma &. Leukemia. 2017;17:728–33.
Paz-Y-Mino C, Burgos R, Morillo SA, Santos JC, Fiallo BF, Leone PE. BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador. Cancer Gen Cytogen. 2002;132:65–67.
Mondal BC, Bandyopadhyay A, Majumdar S, Mukhopadhyay A, Chandra S, Chaudury U, et al. Molecular profiling of chronic myeloid leukemia in Eastern India. Am J Hematol. 2006;81:845–9.
Sharma P, Kumar L, Mohanty S, Kochupillai V. Response to imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts. Ann Hematol. 2010;89:241–7.
Arun AK, Senthamizhselvi A, Mani S, Vinodhini K, Janet NB, Lakshmi KM, et al. Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients. Int Jnl Lab Hem. 2017;39:235–42.
Yaghmaie M, Ghaffari SH, Ghavamzadeh A, Alimoghaddam K, Jahani M, Mousavi SA, et al. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia. Arch Iran Med. 2008;11:247–51.
Osman E-AI, Hamad K, Elmula IMF, Ibrahim ME. Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients. Genet Mol Biol. 2010;33:229–31.
Adler R, Viehman S, Kulisch E, Martiniak Y, Rottgers S, Harbott J, Suttorp M. Correlation of BCR/ABL transcript variants with patients’ characteristics in childhood chronic myeloid leukemia. Eur J Haematol. 2009;82:112–9.
Giona F, Putti MC, Micalizzi C, Menna G, Moletti ML, Santoro N, et al. Long-term results of high dose imatinib in children and adolescents with chronic myeloid leukemia in chronic phase: the Italian experience. Br J Haematol. 2015;170:398–407.
Hasan SK, Sazawal S, Kumar B, Chaubey R, Mishra P, Chaudry VP, et al. Child CML India: b2a2 Transcr Is more Common b3a2 Cancer Genet Cytog. 2006;169:76–77.
Millot F, Suttorp M, Guilhot J, Sedlacek P, De Bont E, Li CK, et al. The International Registry for chronic myeloid leukemia in children and adolescents (I-CML-Ped-Study): objectives and preliminary results. 54th Annual Meeting of the American Society of Hematology. Blood. 2012;120:3741.
Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, Lee MS, O’Brien S, Rios MB, et al. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory and prognostic correlations. Cancer. 1995;76:992–7.
van Rhee F, Hochhaus A, Lin F, Melo JV, Goldman JM, Cross NC. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias. Blood. 1996;87:5213–7.
Lichty BD, Keating A, Callum J, Yee K, Croxford R, Corpus G, et al. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia. Br J Haematol. 1998;103:711–5.
Mills KL, Mackenzie ED, Birnie GD. The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients. Blood. 1988;72:1237–41.
Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, et al. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated front-line with imatinib. Am J Hematol. 2017;92:797–805.
Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pacock C, Smith G, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomized, phase 2 trial. Lancet Haematol. 2017;4:e310–6.
D’Adda M, Farina M, Schieppati F, Cerqui E, Ruggeri G, Ferrari S, et al. An e13a2 type of BCR-ABL transcript has a significant adverse impact on the achievement of a sustained deep molecular response and on the maintenance of a treatment free remission after stopping tyrosine kinase inhibitors. 59th Annual Meeting of the American Society of Hematology. Blood. 2017;130:1589.
Branford S, Yeung OT, Ross DM, Prime JA, Field CR, Altamura K, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with chronic myeloid leukemia. Blood. 2013;121:3818–24.
Mori S, Vagge E, le Coutre P, Abruzzese E, Martino B, Pungolino E, et al. Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study. Am J Hematol. 2015;90:810–4.
Ravandi F, O’Brien S, Cortes JE, Thomas DM, Garris R, Faderl S, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome positive-acute lymphoblastic leukemia. Cancer. 2015;121:4158–64.
Yasukawa M, Ohminami H, Kojima K, Hato T, Hasegawa A, Takahashi T, et al. HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4+T lymphocytes. Blood. 2001;98:1498–505.
Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A, et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentric observational trial. Lancet. 2005;365:657–62.
Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia. 2007;21:2287–95.
Westermann J, Kopp J, van Lessen A, Hecker A-C, Baskaynak G, le Coutre P, et al. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl+chronic myeloid leukaemia. Br J Haematol. 2007;137:297–306.
Ravandi F, Cortes J, Albitar M, Arlinghaus R, Guo JK, Talpaz M, Kantarjian HM. Chronic myelogenous leukaemia with p185 BCR/ABL expression: characteristics and clinical significance. Br J Haematol. 1999;107:581–6.
Verma D, Kantarjian HM, Jones D, Luthra R, Borthakur G, Verstovsek S, et al. Chronic myeloid leukemia with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance. Blood. 2009;114:2232–5.
Pardanani A, Tefferi A, Litzow MR, Zent C, Hogan WJ, McClure R, Viswanatha D. Chronic myeloid leukemia with p190 BCR-ABL: prevalence, morphology, tyrosine kinase inhibitor response, and kinase domain mutation analysis. Blood. 2009;114:3502–3.
Jain P, Romo CG, Khoury HJ, Kantarjian H, Cortes J. Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcript. Haematologica. 2013;8:e141–2.
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomized, open-label, phase 3 trial. Lancet Oncol. 2016;17:612–21.
Qin Y-Z, Jiang Q, Jiang H, Lai Y-Y, Shi H-X, Chen W-M, et al. Prevalence and outcome of uncommon BCR-ABL1 transcripts in patients with CML: data from a single centre. Br J Haematol. 2018; https://doi.org/10.1111/bjh.15453.
Li S, Ilaria RL, Million RP, Daley GQ, Van Etten RA. The P190, P210 and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different leukemogenic activity. J Exp Med. 1999;189:1399–412.
Hai H, Kizilbash NA, Zaidi SHH, Alruwaili J, Shahzad K. Differences in structural elements of Bcr-Abl oncoprotein isoforms in chronic myelogenous leukemia. Bioinformation. 2014;10:108–14.
Reckel S, Hamelin R, Georgeon S, Armand F, Jolliet Q, Chiappe D, et al. Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics. Leukemia. 2017;31:1502–15.
Cutler J, Tahir R, Sreenivasamurthy SK, Mitchell C, Renuse S, Nirujogi RS. Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis. Leukemia. 2017;31:1513–24.
Arana-Trejo RM, Sanchez ER, Ignacio-Barra G, De La Fuerte EB, Garces O, Morales EG, et al. BCR/ABLp210, p190 and p230 fusion genes in 250 mexican patients with chronic myeloid leukaemia. Int J Lab Hematol. 2002;24:145–50.
Quackenbush RC, Reuther GW, Miller JP, Courtney KD, Pear WS, Pendergast AM. Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases. Blood. 2000;95:2913–21.
Molica M, Zacheo I, Diverto D, Alimena G, Breccia M. Long-term outcome of chronic myeloid leukaemia patients with p210 and p190 co-expression at baseline. Br J Haematol. 2015;169:138–53.
Barilà D, Superti-Furga G. An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet. 1998;18:280–2.
Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. Mol Cell. 2003;12:27.37.
Sasaki K, Strom SS, O’Brien S, Jabbour E, Ravandi F, Konopleva M, et al. Relative survival in patients with chronic-phase chronic myeloid leukemia in the tyrosine-kinase inhibitor era: analysis of patients data from six prospective trials. Lancet Hematol. 2015;2:e186–93.
Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM-L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34:2851–7.
The cooperation, the advices and the comments of the members of the International Childhood CML Registry, the GIMEMA CML Working Party, the French, German, and Taiwan CML Study Groups, the Arab LeukemiaNet, and of Mohammed Azzazi, Susan Branford, Richard Clark, Nicholas Cross, Letizia Foroni, Torsten Haferlach, Quian Jiang, Eric Lippert, Junia Melo, and Dietger Niederwieser, are kindly acknowledged. The skilled technical support of Michela Apolinari and Chiara Ferri is kindly acknowledged. This work was supported in part by the ELN Foundation.
The members of the International BCR-ABL1 Study Group
AFRICA: Algeria: Mohamed-Amine Bekadja, Badra Entasoltan, Mourad Nachi, EHU 1er Novembre, Oran; Egypt: Ashraf Elghandour, Manal El Sorady, Alexandria University, Alexandria; Raafat Abdelfattah, Yasser El Nahass, Mohamed Samra, NCI, Cairo; Mohammed Azzazi, Ezat Elsobki, Mohamed Moussa, Ain Shams University, Cairo; Omar Fahmy, Mervat Mattar, Cairo University, Cairo; Samir Eid Shehata, Asuit University, Cairo; Emad Azmy, Mansoura University and Cancer Center, Mansoura; Nigeria: Rahman A. Bolarinwa, Obafemi Awolowo University, Ile-Ife; Tunisia: Samir Eid, Abderrhaim Khelif, Farhat Hached, Teaching Hospital, Sousse; Samia Menif, Pasteur Institute, Tunis. ASIA: Bangladesh: Hafizur Rahman, International Center for Diarrhoeal Disease, Dhaka; China: Xiaojun Huang, Qian Jiang, Peking University People's Hospital and Peking University Inst. of Hematology, Bejin; Yuanxin Ye, Huanling Zhu, West China Hospital, Sichuan University, Sichuan; Suning Chen, The First Affiliated Hospital of Soochow University, Suzhou; India: Neelam Varma, PGIMER, Chandigarh; Prasanth Ganesan, Cancer Inst. (WIA), Chennai; Sadashivudu Gundeti, Nizam's Inst. of Medical Sciences, Hyderabad; Hemant Malhotra, RK Birla Cancer Center, Jaipur; Vivek S. Radhakrishnan, Tata Medical Center, Kolkata; Lalit Kumar, Surender Kumar Sharawat, All India Inst. of Medical Science, New Delhi; Tulika Seth, AIIMS, New Delhi; B.V. Ausekar, Shiddheshwar Cancer Hospital and Research Center, Solapur; Poonkuzhali Balasubramanian, Christian Medical College, Vellore; Iran: Behzad Poopak, Islamic Azada University and Payvand Clinical and Specialty Laboratory, Tehran; Japan: Koiti Inokuchi, Nippon Medical School, Tokyo; Korea S.: Dong-Wook Kim, Seoul St. Mary's Hospital, Leukemia Research Unit, The Catholic University of Korea, Seoul; Oman: Salam Al Kindi, Sultan Qaboos University, Muscat; Philippines: Angelina Mirasol, The Philippines General Hospital, Manila; Saudi Arabia: Mohammed Qari, King Abdul Aziz University Hospital, Jeddah; Singapore: Yeow Tee Goh, Singapore General Hospital, Singapore; Taiwan: Lee-Yung Shih, Chang Gung University and Chang Gung Memorial Hospital, Linkou. AUSTRALIA: Susan Branford, University of Adelaide and University of South Australia, Adelaide. EUROPE: Austria: Thomas Lion, Children’s Cancer Research Institute, Vienna; Peter Valent, Medical University of Vienna, Vienna; Sonja Burgstaller, Joseph Thaler, Klinikum Wels-Grieskirchen, Wels; Croatia: Boris Labar, Renata Zadro, University Hospital Center Zagreb, Zagreb; Czech Republic: Jiri Mayer, Daniela Zackova, University Hospital Brno and Masaryk University, Brno; Edgar Faber, Palacky University, Olomouc; Denmark: Niels Pallisgaard, Sjaellands Universitethospital, Roskilde; France: François Xavier-Mahon, University of Bordeaux, Bordeaux; Eric Lippert, CHU, Brest; Jean Michel Cayuela, Delphine Réa, Hopital Saint Louis, Paris; Frederic Millot; CHU de Poitiers,Poitiers; Germany: Meinolf Suttorp, Universitaetsklinikum Carl Gustav Carus, Dresden; Andreas Hochhaus, Universitaetsklinikum Jena, Jena; Dietger Niederwieser, University of Leipzig, Leipzig; Susanne Saussele, University Clinic Mannheim, Mannheim; Torsten Haferlach, Sabine Jeromine, MLL Muenchner Leukaemielabor, Muenchen; Greece: Panayiotis Panayiotidis, University of Athens and Laikon General Hospital, Athens; Ireland: Eibhlin Conneally, Steve Langabeer, St. James Hospital, Dublin; Israel: Arnon Nagler, Chaim Sheba Medical Center and Tel Aviv University, Tel Aviv; Italy: Serena Rupoli, University of Ancona, Ancona; Nicola Santoro, Azienda Ospedaliero-Universitaria "Policlinico Consorziale", Bari; Francesco Albano, University of Bari, Bari; Fausto Castagnetti, Emanuela Ottaviani, University of Bologna and S.Orsola-Malpighi University Hospital, Bologna; Alessandro Rambaldi, University of Milano and AAST Papa Giovanni XXIII, Bergamo; Fabio Stagno, University of Catania, Catania; Stefano Molica, A. Ospedale Pugliese Ciaccio, Catanzaro; Caterina Biagiotti, Barbara Scappini, University of Florence, Florence; Roberto Lemoli, University of Genova, Genova; Alessandra Iurlo, Fondazione IRCCS Ca' Granda and University of Milano, Milano; Ester Pungolino, Ospedale Niguarda, Milano; Giuseppe Menna, Fara Petruzziello, Ospedale Pausillipon, Napoli; Fabrizio Pane, University Federico II, Napoli; Enrico Gottardi, Giovanna Rege-Cambrin, S. Luigi Gonzaga Hospital and University of Torino, Orbassano; Gianni Binotto, University of Padova, Padova; Maria Caterina Putti, Clinica di Emato-oncologia Pediatrica, Azienda Ospedaliera, Padova; Franca Falzetti, University of Perugia, Perugia; Giuseppe Visani, Ospedale S.Salvatore, Pesaro; Sara Galimberti, University of Pisa, Pisa; Pellegrino Musto, IRCCS-CROB, Rionero in Vulture; Elisabetta Abruzzese, S. Eugenio Hospital, Roma; Massimo Breccia, Fiorina Giona, Sapienza University, Roma; Patrizia Chiusolo, Simona Sica, Policlinico Gemelli, Roma; Carmen Fava, Dario Ferrero, University of Torino, Torino; Mario Tiribelli, University of Udine, Udine; Massimiliano Bonifacio, University of Verona, Verona; Lithuania: Laimonas Griskevicius, Vilnius University, Vilnius; Moldova: Vasile Musteata, State University of Medicine and Pharmacy “N. Testemitanu”, Chisinau; Netherlands: Jeroen Janssen, VU University Medical Center, Amsterdam; Poland: Witold Prejzner, Medical University of Gdansk, Gdansk; Tomasz Sacha, Joanna Waclaw, Jagiellonian University Hospital, Krakow; Portugal: Antonio Medina Almeida, Inst. Portugues de Oncologia de Lisboa Francisco Gentil, Lisboa; Russia: Sergei Kulikov, Anna Turkina, National Research Center for Hematology of Ministry for Healthcare of Russian Federation, Moscow; Serbia: Andrjia Bogdanovic, Clinical Center of Serbia, University of Belgrade, Belgrade; Slovenia: Irena Zupan, University Clinical Center, Ljubljana; Spain: Silvia Marcé, Hospital Germans Trias i Pujol-ICO Badalona, Badalona; Francisco Cervantes, Hospital Clinic Barcelona, IDIBAPS, Barcelona; Juan Luis Steegmann, Hospital Universitario de la Princesa, Madrid; Ukraine: Konstyantyn Kotlyarchuk, SI Inst. of Blood Pathology and Transfusion Medicine, Lviv; United Kingdom: Benedict J. Milner, Aberdeen Royal Infirmary, Aberdeen; Susan Rose, Birmingham Women’s NHS Foundation Trust, Birmingham; Tim Clench, Bristol Royal Infirmary, Bristol; Paula Waits, Bristol Genetics Laboratory, Bristol; Steve Austin, Cardiff and Vale University Health Board, Cardiff; Caroline Wickham, Royal Devon and Exeter NHS Foundation Trust, Exeter; Richard Clark, Royal Liverpool University Hospital, Liverpool; Jane Apperley, Simone Claudiani, Letizia Foroni, Richard Szydlo, Imperial College London, Hammersmith Hospital, London; Emma Burt, The Royal London Hospital, London; Ruth Bescoby, Leanne Cork, Stephen O'Brien, University of Newcastle, Newcastle; Bethaney Green, Sarah Hawtree, Mark Watson, Sheffield Diagnostics Genetics Services, Sheffield. SOUTH AMERICA: Argentina: Raquel Maria Bengiò, Irene Larripa, IIHEMA-Academia Nacional de Medicina, Buenos Aires; Carolina Pavlovsky, FUNDALEU, Hospitalization and Clinical Research Center, Buenos Aires; Beatriz Moiraghi, Hospital JM Ramos Mejia, CABA, Buenos Aires; Brasil: Cristiane Almeida Requiao de Pinna, Federal University Hospital of Bahia, Bahia; Gustavo Henrique Romani Magalhaes, Minas Gerais Federal University-Hospital das Clinicas, Belo Horizonte; Katia Pagnano, University of Campinas, Campinas; Vaneuza Funke, Federal University of Parana, Curitiba; Renato Sampaio Tavares, Hospital das Clinicas da UFG, Goiania; Adriana Prado, Clinical Hospital of Federal University of Goias, Goias; Alita Andrade Azevedo, Centro de Hematologia e Hematoterapia de Pernambuco, Pernambuco; Laura Fogliatto, Hospital de Clinicas de Porto Alegre, Porto Alegre; Simone Bonecker, CEMO/INCA, Rio de Janeiro; Renato Centrone, Inst. Hemomed of Oncology and Hematology, Rio de Janeiro; Artur Moellman, INCA/MS, Rio de Janeiro; Israel Bendit, University of Sao Paulo, Sao Paulo; Monika Conchon, Hospital Santa Marcelina, Sao Paulo; Paraguay: Maria Elida Centurion, Central Hospital of Asuncion, Asuncion; Uruguay: Ana-Ines Prado, Hospital Maciel, Montevideo; Venezuela: JL Lopez, Banco Municipal de Sangre del DC, Caracas.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The members of the International BCR-ABL1 Study Group are listed before the references in alphabetical order, by continent, by country, by town, and by name
About this article
Cite this article
Baccarani, M., Castagnetti, F., Gugliotta, G. et al. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview. Leukemia 33, 1173–1183 (2019). https://doi.org/10.1038/s41375-018-0341-4
Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib
Indian Journal of Hematology and Blood Transfusion (2020)
Nature Reviews Clinical Oncology (2020)
Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells
Investigational New Drugs (2020)
WIREs RNA (2020)